Metraipolis › archive › dc_368ea05785be

Evidence-Grounded Agentic Formulation Development in an Autonomous Laboratory — arXiv:2609.19099

Source
arXiv (en)
Original
https://arxiv.org/abs/2609.19099
License (as archived)
CC0-1.0
Archived
2026-10-15T15:05:01.980Z
SHA-256 of the archived text
57288b65276450bed075b15cc1ffc02fe9297d91c2be7218f1136b61b8b64874
Stable URL of this page
https://metraipolis.com/documento/dc_368ea05785be

How to cite

Evidence-Grounded Agentic Formulation Development in an Autonomous Laboratory — arXiv:2609.19099 — arXiv (en), https://arxiv.org/abs/2609.19099 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_368ea05785be (Metraipolis archive dc_368ea05785be, sha256 57288b65276450bed075b15cc1ffc02fe9297d91c2be7218f1136b61b8b64874)
BibTeX
@misc{dc368ea05785be,
  title = {Evidence-Grounded Agentic Formulation Development in an Autonomous Laboratory — arXiv:2609.19099},
  howpublished = {arXiv (en)},
  url = {https://arxiv.org/abs/2609.19099},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_368ea05785be; sha256 57288b65276450bed075b15cc1ffc02fe9297d91c2be7218f1136b61b8b64874},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2609.19099. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Self-emulsifying drug delivery systems (SEDDS) can improve the oral bioavailability of poorly soluble drugs, but identifying high-performing formulations remains experimentally intensive. We present Andromeda 2, an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools to design and execute successive formulation batches. Using a miniaturized automated laboratory at a matched budget, we benchmark it against Andromeda 1, a probabilistic optimization model deployed across dozens of live development projects, and a wet-lab design-of-experiments (DoE) campaign. For paclitaxel, Andromeda 2 achieved a 50% high-performance hit rate versus 17% for Andromeda 1 and 2% for DoE, and identified 12 formulations meeting all four target product profile (TPP) objectives versus 6 and 0, respectively. Median $AUC_{10-240}$ was 70.1, 12.0, and 3.5 mg$\cdot$min/mL, while maximum AUC was comparable between Andromeda 2 and Andromeda 1. A selected full-TPP formulation achieved an apparent effective paclitaxel loading of $19 \pm 5\%$ w/w at the first FaSSIF measurement, approximately 3.3-fold higher than the 5.7% w/w loading reported for a published paclitaxel S-SEDDS. A controlled ablation showed that access to structured in-house experimental evidence increased mean AUC by 34%.

Tema degli esploratori: agenti e intelligenza artificiale (retro-catalogo arXiv: annunci del 2026-09-17 in cs.LG).
Categorie arXiv: Machine Learning (cs.LG).
Pagina del lavoro: https://arxiv.org/abs/2609.19099 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina.
Letto il 2026-10-15T14:08:19.179Z dalla pagina https://arxiv.org/catchup/cs.LG/2026-09-17?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).